CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 42 enrolled
Drug / intervention
Intranasal Dexmedetomidine +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04237532
NCT04237532Phase 3Completed
CompareCT.gov

Effectiveness of Sublingual Versus Intranasal Administration of Dexmedetomidine for Sedation of Children Undergoing Dental Treatment (A Randomized Controlled Clinical Trial)

Nourhan M.Aly·interventional·Posted Jan 23, 2020·Updated Oct 29, 2020

In Brief

A Phase 3 clinical trial evaluating Intranasal Dexmedetomidine and Sublingual Dexmedetomidine for Anti-anxiety Agents and Moderate Sedation. Completed, enrolled 42 participants across 1 site.

Detailed Summary

The aim of this study is to assess the efficacy of Dexmedetomidine drug either used sublingually or intranasally in managing healthy children during dental treatment

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAnti-anxiety Agents, Moderate Sedation
CountriesEgypt
CollaboratorsAlexandria University

Timeline

Phase 3CompletedFinished
2020202120222023202420252026
First PostedJan 23, 2020
Enrollment StartAug 27, 2019
Primary CompletionAug 1, 2020
Study CompletionAug 10, 2020
TodayJul 2, 2026
Enrollment to primary: 11 monthsPosted 6.4 years ago

Interventions

Intranasal Dexmedetomidinedrug

The mucosal atomizing device will be used intranasally where the sedative drug will be equally divided and sprayed into each nostril while the child semi reclined position.

Sublingual Dexmedetomidinedrug

The mucosal atomizing device will be used sublingually by asking the child to touch their maxillary incisor teeth with the tip of their tongue and instruct the child not to swallow the drug for 30 seconds.